Airways  	Airways  	 NNP	B-NP
allergic  	allergic  	 JJ	I-NP
inflammation  	inflammation  	 NN	I-NP
and  	and  	 CC	O
L.  	L.  	 NNP	O
reuterii  	reuterii  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children  	children  	 NNS	I-NP
Recently 	Recently 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
hypothesized  	hypothesized  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
oral  	oral  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	O
specific  	specific  	 JJ	O
live  	live  	 JJ	O
probiotic  	probiotic  	 JJ	B-NP
strains  	strains  	 NNS	I-NP
may  	may  	 MD	O
have  	have  	 VB	O
therapeutic  	therapeutic  	 JJ	B-NP
potential  	potential  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 JJ	B-NP
inflammation 	inflammation 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
oral  	oral  	 JJ	B-NP
L.  	L.  	 NNP	I-NP
reuteri  	reuteri  	 VBD	O
DSM  	DSM  	 NNP	B-NP
17938  	17938  	 CD	O
administration  	administration  	 NN	B-NP
( 	( 	 -LRB-	O
1X108CFU 	1X108CFU 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
in  	in  	 IN	O
airways  	airways  	 JJ	B-NP
allergic  	allergic  	 JJ	I-NP
inflammation  	inflammation  	 NN	I-NP
in  	in  	 IN	O
mild  	mild  	 JJ	O
persistent  	persistent  	 JJ	O
asthmatic  	asthmatic  	 JJ	B-NP
children 	children 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
DBPC  	DBPC  	 NNP	B-NP
randomized  	randomized  	 JJ	I-NP
study  	study  	 NN	I-NP
we  	we  	 PRP	O
selected  	selected  	 VBD	O
50  	50  	 CD	O
children  	children  	 NNS	O
( 	( 	 -LRB-	O
6-14  	6-14  	 CD	O
years  	years  	 NNS	O
old 	old 	 JJ	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
affected  	affected  	 VBN	O
by  	by  	 IN	O
mild  	mild  	 JJ	O
persistent  	persistent  	 JJ	O
asthma  	asthma  	 NN	B-NP
( 	( 	 -LRB-	O
GINA  	GINA  	 NNP	B-NP
step  	step  	 NN	I-NP
2 	2 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
allergic  	allergic  	 JJ	O
to  	to  	 TO	O
HDM 	HDM 	 NNP	B-NP
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
run-in  	run-in  	 JJ	O
period  	period  	 NN	O
( 	( 	 -LRB-	O
T-2 	T-2 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
children  	children  	 NNS	O
were  	were  	 VBD	O
submitted  	submitted  	 VBN	O
to  	to  	 TO	O
medical  	medical  	 JJ	B-NP
examination 	examination 	 NN	I-NP
,  	,  	 ,	O
prick  	prick  	 JJ	O
tests  	tests  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
main  	main  	 JJ	O
respiratory  	respiratory  	 JJ	B-NP
allergens 	allergens 	 NN	I-NP
,  	,  	 ,	O
spirometry  	spirometry  	 NN	B-NP
and  	and  	 CC	O
children  	children  	 NNS	B-NP
asthma  	asthma  	 JJ	I-NP
control  	control  	 NN	I-NP
test  	test  	 NN	I-NP
( 	( 	 -LRB-	O
C-ACT 	C-ACT 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
selected  	selected  	 VBD	O
only  	only  	 RB	O
the  	the  	 DT	O
children  	children  	 NNS	O
with  	with  	 IN	O
well  	well  	 RB	O
controlled  	controlled  	 VBN	B-NP
asthma  	asthma  	 NN	I-NP
( 	( 	 -LRB-	O
C-ACT  	C-ACT  	 NNP	B-NP
> 	> 	 CD	O
19  	19  	 CD	O
and  	and  	 CC	O
FEV1 	FEV1 	 CD	B-NP
>  	>  	 CD	O
80 	80 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
After  	After  	 IN	O
two  	two  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
T0 	T0 	 NNP	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
children  	children  	 NNS	O
were  	were  	 VBD	O
allocated  	allocated  	 VBN	O
into  	into  	 IN	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
FeNO  	FeNO  	 NN	B-NP
was  	was  	 VBD	O
measured  	measured  	 VBN	O
and  	and  	 CC	O
the  	the  	 DT	O
breath  	breath  	 NN	B-NP
condensate  	condensate  	 NNS	I-NP
was  	was  	 VBD	O
collected 	collected 	 VBN	O
.  	.  	 .	O
Group  	Group  	 NNP	O
A  	A  	 NNP	O
children  	children  	 NNS	O
were  	were  	 VBD	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 NN	O
( 	( 	 -LRB-	O
5  	5  	 CD	O
drops  	drops  	 NNS	O
per  	per  	 IN	O
day 	day 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
Group  	Group  	 NNP	B-NP
B  	B  	 NNP	I-NP
children  	children  	 NNS	I-NP
with  	with  	 IN	O
L.  	L.  	 NNP	B-NP
reuteri  	reuteri  	 NNS	I-NP
( 	( 	 -LRB-	O
108CFU  	108CFU  	 FW	O
=5  	=5  	 FW	O
drops  	drops  	 FW	O
per  	per  	 FW	O
day 	day 	 NN	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
60  	60  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
After  	After  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	B-NP
period  	period  	 NN	I-NP
( 	( 	 -LRB-	O
T1 	T1 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
medical  	medical  	 JJ	B-NP
examination 	examination 	 NN	I-NP
,  	,  	 ,	O
C-ACT 	C-ACT 	 NNP	B-NP
,  	,  	 ,	O
spirometry 	spirometry 	 NN	B-NP
,  	,  	 ,	O
FeNO  	FeNO  	 JJ	B-NP
measurement  	measurement  	 NN	I-NP
and  	and  	 CC	O
exaled  	exaled  	 JJ	B-NP
breath  	breath  	 NN	I-NP
condensate  	condensate  	 NN	I-NP
analysis 	analysis 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
FeNO  	FeNO  	 JJ	B-NP
values  	values  	 NNS	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
( 	( 	 -LRB-	O
p=0,045 	p=0,045 	 NNP	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
L.  	L.  	 NNP	O
reuteri  	reuteri  	 JJ	B-NP
group  	group  	 NN	I-NP
but  	but  	 CC	O
not  	not  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 JJ	O
group  	group  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
end  	end  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
( 	( 	 -LRB-	O
T1 	T1 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
cytokines  	cytokines  	 JJ	B-NP
exam  	exam  	 NN	I-NP
showed  	showed  	 VBD	O
an  	an  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
IL-10  	IL-10  	 CD	B-NP
levels  	levels  	 NNS	I-NP
( 	( 	 -LRB-	O
p  	p  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
0.05 	0.05 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
IL-2  	IL-2  	 CD	B-NP
levels  	levels  	 NNS	I-NP
( 	( 	 -LRB-	O
p  	p  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
0.05 	0.05 	 CD	O
)  	)  	 -RRB-	O
only  	only  	 RB	O
in  	in  	 IN	O
L.  	L.  	 NNP	O
reuteri  	reuteri  	 JJ	B-NP
group  	group  	 NN	I-NP
at  	at  	 IN	O
T1 	T1 	 CD	O
.  	.  	 .	O
No  	No  	 DT	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
FEV1  	FEV1  	 CD	B-NP
values  	values  	 NNS	I-NP
and  	and  	 CC	O
C-ACT  	C-ACT  	 JJ	B-NP
score  	score  	 NN	I-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
groups 	groups 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
these  	these  	 DT	O
data  	data  	 NNS	O
showed  	showed  	 VBD	O
that  	that  	 IN	O
L.  	L.  	 NNP	B-NP
reuteri  	reuteri  	 NNS	I-NP
( 	( 	 -LRB-	O
108  	108  	 CD	O
CFU 	CFU 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
reducing  	reducing  	 VBG	O
bronchial  	bronchial  	 JJ	B-NP
inflammation  	inflammation  	 NN	I-NP
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children 	children 	 NNS	I-NP
.  	.  	 .	O
No  	No  	 DT	O
significant  	significant  	 JJ	O
effect  	effect  	 NN	O
was  	was  	 VBD	O
found  	found  	 VBN	O
on  	on  	 IN	O
FEV1  	FEV1  	 CD	B-NP
values  	values  	 NNS	I-NP
and  	and  	 CC	O
C-ACT  	C-ACT  	 JJ	B-NP
score 	score 	 NN	I-NP
,  	,  	 ,	O
probably  	probably  	 RB	O
because  	because  	 IN	O
we  	we  	 PRP	O
selected  	selected  	 VBD	O
children  	children  	 NNS	O
with  	with  	 IN	O
well  	well  	 RB	O
controlled  	controlled  	 VBN	B-NP
asthma 	asthma 	 NN	I-NP
.  	.  	 .	O
